NCT03465787View on ClinicalTrials.gov

A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

April 9, 2018

Primary Completion Date

October 26, 2022

Study Completion Date

October 26, 2022

Conditions
Schizophrenia
Interventions
DRUG

Lurasidone HCL 160 mg

Lurasidone HCL 2 80mg tablets, QD

DRUG

Quetiapine XR 600 mg

Quetiapine XR 2 300 mg tablets, QD

Trial Locations (1)

07061

Borame Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Bukwang Pharmaceutical

INDUSTRY